Q-omics provides the consensus-scored SLC8A2 profile across patient tissues and cancer cell-line models. SLC8A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC8A2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SLC8A2 RNA expression shows 17,946 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where SLC8A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC8A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC8A2 survival associations across molecular data types. SLC8A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC8A2 RNA expression–survival associations across cancer types. High SLC8A2 expression shows unfavorable associations in KIRC, OV and UCS, but favorable associations in LGG, SCLC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC8A2 RNA expression.
This table summarizes SLC8A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SLC8A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC8A2 shows lower tumor expression in BLCA, UCEC, STAD and READ and higher tumor expression in KIRP and BRCA. The BLCA box plot shows higher SLC8A2 RNA expression in normal versus tumor tissue (log2 FC = −2.477, t-test p = .006).
This table shows molecular features associated with SLC8A2 in patient tissues and cancer cell lines. In patient samples, SLC8A2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC8A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
